RDY
Dr. Reddy’s Laboratories Ltd ADR
NYSE: RDY · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$13.73
-2.14% today
Updated 2026-04-29
Market cap
$11.46B
P/E ratio
19.07
P/S ratio
0.03x
EPS (TTM)
$0.72
Dividend yield
0.67%
52W range
$13 – $16
Volume
2.4M
Dr. Reddy’s Laboratories Ltd ADR (RDY) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$13.73
12-Month target
$13.43
2030 Target
$20.95
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6B | $214.4B | $245.9B | $279.2B | $325.5B | $368.7B | $417.7B | $473.1B | $535.9B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 13.27% (capped 20%) · P/E: 19.07x (capped 25x) · Margin: 16.40%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.